28-Oct-2026 20:56:45
AARTIPHARMGeneral news
AARTIPHARM Q2 : CONS NET PROFIT UP 248.8% AT ₹71.47 CR (YOY), DOWN 6.1% (QOQ). STRONG (ON 1ST LOOK)
Revenue up 45.9% at ₹610.45 Cr (YOY), up 13.9% (QOQ). Ebitda up 109.2% at ₹135.62 Cr (YOY), down 0.7% (QOQ); margins 22.2% v 15.5% (YOY), 25.5% (QOQ). Caution: ₹2.04 Cr exceptional provision for Gujarat stamp duty; ₹57.46 Cr balance duty/penalty disclosed as contingent liability, writ pending. CFO Piyush Lakhani resigns effective October 30; Vibha Thakkar appointed CFO from October 31.
Aarti Pharmalabs Ltd
Open attachment